Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has seen a rise in its stock price by 5.32 in relation to its previous close of 4.98. However, the company has experienced a 7.04% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-14 that VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.
Is It Worth Investing in Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Right Now?
Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VNDA is 55.21M, and currently, short sellers hold a 5.84% ratio of that floaft. The average trading volume of VNDA on November 27, 2024 was 616.72K shares.
VNDA’s Market Performance
VNDA’s stock has seen a 7.04% increase for the week, with a 11.83% rise in the past month and a 0.48% gain in the past quarter. The volatility ratio for the week is 3.26%, and the volatility levels for the past 30 days are at 4.14% for Vanda Pharmaceuticals Inc The simple moving average for the past 20 days is 4.42% for VNDA’s stock, with a 5.08% simple moving average for the past 200 days.
Analysts’ Opinion of VNDA
Many brokerage firms have already submitted their reports for VNDA stocks, with H.C. Wainwright repeating the rating for VNDA by listing it as a “Buy.” The predicted price for VNDA in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on October 31, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VNDA reach a price target of $11. The rating they have provided for VNDA stocks is “Overweight” according to the report published on July 11th, 2024.
Jefferies gave a rating of “Hold” to VNDA, setting the target price at $12 in the report published on February 25th of the previous year.
VNDA Trading at 9.11% from the 50-Day Moving Average
After a stumble in the market that brought VNDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.30% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 3.26%, as shares surge +14.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.86% upper at present.
During the last 5 trading sessions, VNDA rose by +6.94%, which changed the moving average for the period of 200-days by +29.06% in comparison to the 20-day moving average, which settled at $5.02. In addition, Vanda Pharmaceuticals Inc saw 24.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNDA starting from Mitchell Stephen Ray, who sale 5,000 shares at the price of $5.17 back on Nov 14 ’24. After this action, Mitchell Stephen Ray now owns 44,857 shares of Vanda Pharmaceuticals Inc, valued at $25,863 using the latest closing price.
Mitchell Stephen Ray, the Director of Vanda Pharmaceuticals Inc, proposed sale 5,000 shares at $5.40 during a trade that took place back on Nov 14 ’24, which means that Mitchell Stephen Ray is holding shares at $27,000 based on the most recent closing price.
Stock Fundamentals for VNDA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.92 for the gross margin
The net margin for Vanda Pharmaceuticals Inc stands at -0.09. The total capital return value is set at -0.07. Equity return is now at value -3.02, with -2.55 for asset returns.
Currently, EBITDA for the company is -10.94 million with net debt to EBITDA at 3.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.12. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.85.
Conclusion
In a nutshell, Vanda Pharmaceuticals Inc (VNDA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
